Exelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in conjunction with the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011 at McCormick Place in Chicago, Illinois. Cabozantinib, the company’s most advanced solely owned product candidate, will be the subject of three oral presentations at the meeting. In addition, Exelixis will hold an investor/analyst briefing during the meeting to review the latest data for the compound
